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It has been almost thirty years since federal regulations
governing research with human subjects were first developed. Since
that time, the world of biomedical research has changed dramatically.
1
Not only has the amount of research increased exponentially, but
the context in which research is conducted also has changed. Twenty
years ago, medical research was virtually the exclusive province of
academic medical centers, which designed, conducted, and reported
on studies financed primarily by the National Institutes of Health.
Today, research occurs in a broad range of nonacademic settings,
including for-profit contract research organizations, community
hospitals, and private physicians’ offices. In addition, an increasingly
large portion of research funding comes from private sources. This
shift away from an academic model of scientific research to a system
more closely aligned with private commercial interests has
complicated the process of research oversight, by both reducing the
transparency of the research enterprise and increasing the
prevalence of conflicts of interest.
In November 2001, Seton Hall Law School, Seton Hall University
Graduate School of Medical Education, and the American Society of
Law, Medicine & Ethics sponsored a day-long symposium to explore
the legal, ethical, and public policy implications of the shift in
research away from academic medical centers. Supported by a
generous grant from the law firm of Gibbons Del Deo Dolan
Griffinger & Vecchione, the symposium brought together leaders in
the fields of law, medicine, and bioethics, many of whom have
contributed papers to this issue of the Seton Hall Law Review.
The paper by Bernard Lo and Michelle Groman of the
University of California at San Francisco Medical Center, which
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expands on Dr. Lo’s keynote address at the beginning of the
symposium, highlights one of the most significant deficiencies in the
current regulatory regime—the limited applicability of federal
human subject protections to research that is not funded by the
2
federal government. While some privately-funded research is subject
to federal regulatory oversight, either because it involves products
regulated by the Food and Drug Administration or because it takes
place in institutions that have signed multiple project assurances with
the federal government, a significant proportion of privately-funded
3
research fits into neither of these categories. One of the most
important recommendations of the National Bioethics Advisory
Commission (NBAC), therefore, was its call for a uniform system of
federal regulation for all human subject research, regardless of
4
source of funding. In addition to discussing NBAC’s rationale for
expanding federal jurisdiction over research, Lo and Groman’s paper
also addresses several other important NBAC recommendations,
including those designed to reduce unnecessary regulation of low-risk
activities; to increase the proportion of outside members of
institutional review boards (IRBs), the committees that review and
approve research protocols under the federal regulations; to reform
the requirements for waiving informed consent to research; and to
provide greater guidance for IRBs’ process of assessing research risks.
One of the challenges of overseeing research conducted in
nonacademic settings is identifying an appropriate body to review
and approve research protocols. As research increasingly moves away
from academic medical centers, many of the settings in which
research is conducted do not have IRBs. David Forster’s paper
examines a type of organization that has emerged to fill this void—
5
the independent institutional review board. These organizations,
which include the company for which Mr. Forster serves as general
counsel, Western Institutional Review Board, operate separate from
and unaffiliated with institutions that conduct research activities. Mr.
Forster identifies several concerns that have been raised about
independent IRBs and offers suggestions for addressing these
concerns, including procedures for minimizing the influence of
conflicts of interest. In addition, he argues that independent IRBs
offer important advantages over traditional IRBs in several respects.
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The issue of conflicts of interest is the subject of an extensive
analysis by Mark Barnes and Patrik S. Florencio, both lawyers with the
6
law firm of Ropes & Gray in New York. Financial conflicts of interest
“lie at the core of ethical issues surrounding clinical trials,” Barnes
and Florencio argue, “and the anecdotal evidence is that these
7
conflicts are widespread.” The potential for commercial interests to
influence the integrity of research is the result of more than simply
private sponsorship of particular studies. Researchers may have
financial investments in the drugs or devices under investigation, or
they may own stakes in the companies that are sponsoring their
studies. In addition, researchers may receive stipends, speaking and
consulting fees, and other gifts from research sponsors. The
potential influence of financial considerations is most apparent in
for-profit organizations involved in research, such as contract
research organizations and site management organizations, which
“are beholden to their shareholders and less encumbered by
8
academic ideals.” Barnes and Florencio provide a careful analysis of
the current federal regulations’ application to conflicts of interest,
identify their gaps, and describe several proposed approaches to
reforming the system.
Nancy Dubler’s commentary offers a broad perspective on the
9
ethical challenges raised by the changing research environment. Of
particular concern to Dubler is the process of obtaining the informed
consent of individuals who enroll in research protocols. Criticizing
the lengthy, legalistic, and often incomprehensible consent forms
currently in use, she argues that the informed consent process must
“engage[] the subject on an escalating plane of complexity and
10
abstraction.”
Real reform, she argues, will require a significant
investment of time and money, and those who profit from research
must be willing to foot the bill.
While the focus of most of the papers in this issue is research
outside of academic medical centers, Nancy King’s examination of
clinical innovation reminds us that the use of untested medical
interventions within academic settings also may evade effective
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11

oversight. The reason stems from the definition of research under
the federal regulations, which applies only to “systematic
investigation[s] . . . designed to develop or contribute to
12
generalizable knowledge.”
Because the use of untested medical
interventions in the treatment of individual patients generally lacks
“the theoretical and empirical preclinical groundwork that
characterizes the search for knowledge generalizable beyond an
13
individual patient,” King explains, it is not considered research, and
therefore need not be submitted for IRB review. King argues that,
despite this definitional problem, clinical innovation and research
share important similarities, including “lack of data, lack of
experience, and often, significant imbalances between benefits and
14
burdens.”
Indeed, she argues that innovative treatments may
actually involve greater uncertainty than research, as research must
be supported by preclinical data, while the basis for innovation might
15
simply be “reasoning and intuition alone.” Accordingly, she argues
that for most, if not all, innovations, the type of prior review and
standardized informed consent processes that govern research would
be appropriate.
The papers in this issue highlight both the promises and perils
of the new direction in which biomedical research is heading. On
the one hand, new sources of funding and incentives, greater access
to potential subjects, and innovative collaborations between
government, industry, and academia have created enormous
opportunities for scientific advances. On the other hand, because
our regulatory system has failed to keep pace with many of these
changes, much of this new research occurs with only minimal
oversight, creating risks for both individual subjects and the integrity
of the research enterprise itself. Closing these gaps presents an
important challenge to policy makers in the years ahead.
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